申请人:Rigel Pharmaceuticals, Inc.
公开号:US08309566B2
公开(公告)日:2012-11-13
This invention is directed to compounds of formula (I):
where
n, m, Y, R1, R2, R3, R4 and R5 are disclosed herein, as isolated stereoisomers or mixtures thereof, or as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising the compounds of formula (I); and methods of using the compounds and the pharmaceutical compositions in treating diseases or conditions associated with JAK2 activity.
本发明涉及公式(I)化合物,其中n,m,Y,R1,R2,R3,R4和R5在此处披露,可以作为隔离的立体异构体或其混合物,或其药学上可接受的盐;包括公式(I)化合物的制药组合物;以及使用该化合物和制药组合物治疗与JAK2活性相关的疾病或病症的方法。